205 related articles for article (PubMed ID: 34414672)
1. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Shisha T; Posch MG; Lehmann J; Feifel R; Junt T; Hawtin S; Schuemann J; Avrameas A; Danekula R; Misiolek P; Siegel R; Gergely P
Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):553-566. PubMed ID: 37532923
[TBL] [Abstract][Full Text] [Related]
3. Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need.
Klopp-Schulze L; Shaw JV; Dong JQ; Khandelwal A; Vazquez-Mateo C; Goteti K
Clin Pharmacol Ther; 2022 Aug; 112(2):297-306. PubMed ID: 35390178
[TBL] [Abstract][Full Text] [Related]
4. Asia-Inclusive Global Development of Enpatoran: Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial.
Klopp-Schulze L; Gopalakrishnan S; Yalkinoglu Ö; Kuroki Y; Lu H; Goteti K; Krebs-Brown A; Nogueira Filho M; Gradhand U; Fluck M; Shaw J; Dong J; Venkatakrishnan K
Clin Pharmacol Ther; 2024 Jun; 115(6):1346-1357. PubMed ID: 38415785
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
7. Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial.
McKinnon JE; Santiaguel J; Murta de Oliveira C; Yu D; Khursheed M; Moreau F; Klopp-Schulze L; Shaw J; Roy S; Kao AH;
Clin Transl Sci; 2023 Dec; 16(12):2640-2653. PubMed ID: 37873555
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers.
Yamakawa N; Tago F; Nakai K; Kitahara Y; Ikari S; Hojo S; Hall N; Aluri J; Hussein Z; Gevorkyan H; Maruyama T; Ishizaka S; Yagi T
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):363-375. PubMed ID: 36219471
[TBL] [Abstract][Full Text] [Related]
9. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
12. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
16. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals.
Hu Y; Zhang H; Wu M; Liu J; Li X; Zhu X; Li C; Chen H; Liu C; Niu J; Ding Y
Expert Opin Investig Drugs; 2021 Mar; 30(3):263-269. PubMed ID: 33405993
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.
Gane E; Pastagia M; Schwertschlag U; De Creus A; Schwabe C; Vandenbossche J; Slaets L; Fevery B; Smyej I; Wu LS; Li R; Siddiqui S; Oey A; Musto C; Van Remoortere P
Antivir Ther; 2021 May; 26(3-5):58-68. PubMed ID: 35485332
[TBL] [Abstract][Full Text] [Related]
20. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
